C54
Conditions
Interventions
Group 1: Immunohistochemical evaluation of PSMA expression in malignant cervical tissue.
Group 2: Immunohistochemical evaluation of the PSMA status of healthy endometrium.
Sponsors
Universitätsklinikum Freiburg Klinik für Frauenheilkunde
Eligibility
Sex/Gender
Female
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Patients with histologically verified invasive endometrial carcinoma are included in this study.
Exclusion criteria
Exclusion criteria: - no declaration of consent - other oncological disease - intake of selective oestrogen receptor modulators (SERM, for example tamoxifen) - after ovarian stimulation therapy - histologically proved sarcoma, neuroendocrine tumour or mixed tumour - cytostatic or radiotherapy administered before tissue sampling
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Description of the PSMA Expression within the endometrium and endometrial carcinoma on previously removed tissue, using immunohistochemistry and immunofluorescence, as well as proteomic analyses if necessary. | — |
Secondary
| Measure | Time frame |
|---|---|
| Depending on PSMA status (both tumour cells and tumour neovasculature): Survival Disease free survival (dfs). Clinical parameters: Age at time of diagnosis, menopausal status, FIGO stage at time of diagnosis, distant metastasis, body-mass index, use of hormone replacement therapy, family history, Number of births, postoperative radio- or chemotherapy. Histopathological parameters: pTNM stage, histological subtype (endometrioid, mucinous), grading, lymphatic, venous and perineural sheath infiltration, myometrical depth of invasion, three-dimensional tumour size in centimetres, hormone receptor status. | — |
Countries
Germany
Contacts
Public ContactClara Unger
Universitätsklinikum Freiburg Klinik für Frauenheilkunde
Outcome results
None listed